Small Pharma

Small Pharma works on the development of two drugs. Together with Imperial College London, they are developing intravenous administration DMT. The other project is a variant on ketamine (SPL801B).

Small Pharma

“Many valuable drug development opportunities, either from academia or from discovery-focused biotech companies, lose their way in development and never reach the patients who should benefit from them. Small Pharma is dedicated to identifying these opportunities and ensuring that the value in the underlying pharmaceutical assets is preserved.”

In April 2021, Small Pharma completed a broker led subscription receipt financing of $45 million and a non-brokered convertible note financing of $4 million.

The company are listed TSXV (Canadian) stock exchange under the ticker DMT.

Key Staff

Peter Rands – CEO


Company Information

Small Pharma Website

January, 2019


Compounds of Interest
DMT Ketamine

Topics of Interest

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships

Company News

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial (, 28 February 2024)
Small Pharma today announced that the first patient has been dosed in the company’s Phase IIa clinical trial for its lead DMT candidate, SPL026, which, in combination with psychotherapy, is intended to serve as a possible treatment of Major Depressive Disorder.

Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder (, 15 November 2021)
Small Pharma today confirms, following positive discussions with the U.S. Food and Drug Administration, that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a DMT-assisted therapy for the treatment of major depressive disorder.

DMT: A Trip To Get Away From Depression? (, 03 December 2021)


HQ / Office 6-8 Bonhill St, London EC2A 4BX, UK